Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP

Peter Lin MD, CCFP

Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, Ontario

Dr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.

Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.

Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.

Disclosures

  • Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics

Recent Contributions to PracticeUpdate:

  1. Drug–Drug Interactions With Statins and Select Agents Used in Cardiovascular Disease
  2. Triglyceride and HDL-C Levels Predict Diabetic Kidney Disease in Type 2 Diabetes
  3. Lower Diastolic Blood Pressure Leads to Subclinical Myocardial Damage and Cardiac Events
  4. Validation and Comparison of Imaging-Based Scores for Prediction of Early Stroke Risk After Transient Ischaemic Attack
  5. LDL Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
  6. Rivaroxaban Associated With Increased Bleeding Risks vs Dabigatran in Elderly Patients With Nonvalvular Atrial Fibrillation
  7. Heart Failure Associated With Current Use of NSAIDs
  8. Amoxicillin Noninferior to Tetracycline in Bismuth Quadruple Therapy for Helicobacter pylori Eradication Following Treatment Failure
  9. Lowering of LDL-Cholesterol With Statins and Non-Statins Associated With Cardiovascular Risk Reduction
  10. The Potential Hazards of Codeine Use in Children

Most Read This Week

Recently Updated